Business Context and Reporting Period
Company: Entero Therapeutics, Inc. (Note: Metadata referenced "Gridai Technologies Corp." but the filing is for Entero Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2025
Event: Completion of a Share Exchange Agreement with GridAI Corp. and its stockholders.
Key Financial Metrics and Transaction Details
This filing details a strategic acquisition rather than standard periodic financial results. Key transaction metrics include:
- Purchase Price Structure:
- 424,348 shares of Entero Common Stock (representing 19.99% of outstanding shares).
- 38,801,546 shares of Series H Non-Voting Convertible Preferred Stock.
- Dilution Impact: The Common Shares and maximum Conversion Shares represent 82.5% of issued and outstanding Common Stock on a fully-diluted basis.
- Target Asset: GridAI owned 75% of AMPX UK Holdings, a Cayman Islands company.
- Liquidity Covenant: Entero must consummate a financing with gross proceeds of at least $3 million within 30 days of closing and maintain a minimum of $2,000,000 in available cash.
- Stockholders' Equity: The company asserts it now holds at least $2.5 million in stockholders' equity to meet Nasdaq listing requirements.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the period. Material changes are structural and operational:
- Capital Structure: Significant issuance of new equity (Common and Preferred) to acquire GridAI.
- Ownership: Sellers (GridAI stockholders) now hold a controlling interest (82.5% on a fully-diluted basis).
- Board Composition: Sellers may designate two directors immediately, with the right to appoint five out of seven directors upon full conversion of Preferred Stock.
- Listing Status: The transaction was executed to address a prior Nasdaq non-compliance notice regarding minimum stockholders' equity.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Covenants:
- Stockholder Approval: A meeting must be held promptly to approve the conversion of Series H Preferred Stock into Common Stock.
- Employee Incentives: Entero agreed to issue up to 2,000,000 restricted stock awards and grant options for up to 3,800,000 shares (exercise price $0.66) to GridAI/AMPX personnel.
- Registration Rights: Entero must file a registration statement for the resale of new shares within 15 days of preparing required financial statements and seek effectiveness within 90 days.
Risks and Contingencies:
- Delisting Risk: While the company believes it has regained compliance with Nasdaq Rule 5550(b)(1), there is no assurance of continued listing until Nasdaq makes a final determination.
- Financing Risk: Failure to secure the required $3 million financing within 30 days or maintain $2 million cash reserves constitutes a breach of the Share Exchange Agreement.
- Conversion Conditions: The conversion of Preferred Stock is tied to six specific business milestones for AMPX. If certain legacy securities are not cancelled by December 31, 2025, the conversion ratio will adjust from 1:1,000 to 1:1,483.93.
Important Facts for Investor Verification
- Verify the successful consummation of the $3 million financing covenant within 30 days of September 30, 2025.
- Confirm the final determination by Nasdaq regarding the company's compliance with minimum stockholders' equity requirements.
- Monitor the timeline for the Stockholder Meeting required to approve the conversion of Series H Preferred Stock.
- Review the specific "milestone events" for AMPX that trigger the conversion of Preferred Stock into Common Stock.
- Check for the filing of the Registration Statement for the resale of the new shares within the mandated 15-day window.